Evidence map›Paper›PMID 28039608›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2017

HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.

Suresh Bugide, Vijay Kumar Gonugunta, Vasudevarao Penugurti, Vijaya Lakshmi Malisetty, Ratna K Vadlamudi, Bramanandam Manavathi

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Suresh BugideDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India.
Vijay Kumar GonuguntaDepartment of Obstetrics and Gynecology, UT Health Science Center, San Antonio, USA.
Vasudevarao PenugurtiDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India.
Vijaya Lakshmi MalisettyDepartment of Biotechnology, Acharya Nagarjuna University, Guntur, AP, India.
Ratna K VadlamudiDepartment of Obstetrics and Gynecology, UT Health Science Center, San Antonio, USA.
Bramanandam ManavathiDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India. manavbrahma@gmail.com.
University of Hyderabad · INThe University of Texas Health Science Center at San Antonio · USAcharya Nagarjuna University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHematopoietic PBX interacting protein (HPIP), a scaffold protein, is known to regulate the proliferation, migration and invasion in different cancer cell types. The aim of this study was to assess the role of HPIP in ovarian cancer cell migration, invasion and epithelial-mesenchymal transition (EMT), and to unravel the mechanism by which it regulates these processes.

methodsHPIP expression was assessed by immunohistochemistry of tissue microarrays containing primary ovarian tumor samples of different grades. OAW42, an ovarian carcinoma-derived cell line exhibiting a high HPIP expression, was used to study the role of HPIP in cell migration, invasion and EMT. HPIP knockdown in these cells was achieved using a small hairpin RNA (shRNA) approach. Cell migration and invasion were assessed using scratch wound and transwell invasion assays, respectively. The extent of EMT was assessed by determining the expression levels of Snail, Vimentin and E-cadherin using Western blotting. The effect of HPIP expression on AKT and MAPK activation was also investigated by Western blotting. Cell viabilities in response to cisplatin treatment were assessed using a MTT assay, whereas apoptosis was assessed by determining caspase-3 and PARP cleavage in ovarian carcinoma-derived SKOV3 cells.

resultsWe found that HPIP is highly expressed in high-grade primary ovarian tumors. In addition, we found that HPIP promotes the migration, invasion and EMT in OAW42 cells and induces EMT in these cells via activation of the PI3K/AKT pathway. The latter was found to lead to stabilization of the Snail protein and to repression of E-cadherin expression through inactivation of GSK-3β. We also found that HPIP expression confers cisplatin resistance to SKOV3 cells after prolonged exposure and that its subsequent knockdown decreases the viability of these cells and increases caspase-3 activation and PARP proteolysis in these cells following cisplatin treatment.

conclusionsFrom these results we conclude that HPIP expression is associated with high-grade ovarian tumors and may promote their migration, invasion and EMT, a process that is associated with metastasis. In addition, we conclude that HPIP may serve as a potential therapeutic target for cisplatin resistant ovarian tumors.

Indexed as

Cell DeathCell Line, TumorCell MovementCell ProliferationCisplatinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGene Knockdown TechniquesGene SilencingHumansIntracellular Signaling Peptides and ProteinsNeoplasm GradingNeoplasm InvasivenessOvarian NeoplasmsPhosphatidylinositol 3-KinasesCisplatinHCFC1R1 protein, humanIntracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSnail Family Transcription FactorsCell migrationEpithelial-mesenchymal transition (EMT)HPIP/PBXIP1Ovarian cancerPI3K/AKT pathway

Identifiers

PMID28039608
PMCPMC13001559
OpenAlexW2564526526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.